Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aerie Pharmaceuticals stock | 9.92

Own Aerie Pharmaceuticals stock in just a few minutes.


Fact checked

Aerie Pharmaceuticals, Inc is a drug manufacturers—specialty & generic business based in the US. Aerie Pharmaceuticals shares (AERI) are listed on the NASDAQ and all prices are listed in US Dollars. Aerie Pharmaceuticals employs 380 staff and has a trailing 12-month revenue of around USD$81.6 million.

How to buy shares in Aerie Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aerie Pharmaceuticals. Find the stock by name or ticker symbol: AERI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aerie Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$9.92, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aerie Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aerie Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Aerie Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Aerie Pharmaceuticals's share price has had significant negative movement.

Its last market close was USD$9.92, which is 54.05% down on its pre-crash value of USD$21.59 and 8.87% down on the lowest point reached during the March crash when the shares fell as low as USD$10.8.

If you had bought USD$1,000 worth of Aerie Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$581.77 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$479.73.

Aerie Pharmaceuticals share price

Use our graph to track the performance of AERI stocks over time.

Aerie Pharmaceuticals shares at a glance

Information last updated 2020-10-21.
Latest market close USD$9.92
52-week range USD$10.22 - USD$26.26
50-day moving average USD$11.4553
200-day moving average USD$13.2857
Wall St. target price USD$28.54
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-5.169

Buy Aerie Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aerie Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aerie Pharmaceuticals price performance over time

Historical closes compared with the close of $9.92 from 2020-10-19

1 week (2020-11-20) -17.64%
1 month (2020-10-30) -6.50%
3 months (2020-08-28) -7.81%
6 months (2020-05-29) -29.29%
1 year (2019-11-29) -47.76%
2 years (2018-11-29) -75.85%
3 years (2017-11-29) -84.09%
5 years (2015-11-27) -63.62%

Aerie Pharmaceuticals financials

Revenue TTM USD$81.6 million
Gross profit TTM USD$42.3 million
Return on assets TTM -36.28%
Return on equity TTM -164.34%
Profit margin -247.36%
Book value $1.931
Market capitalisation USD$424.2 million

TTM: trailing 12 months

Shorting Aerie Pharmaceuticals shares

There are currently 8.8 million Aerie Pharmaceuticals shares held short by investors – that's known as Aerie Pharmaceuticals's "short interest". This figure is 6.2% up from 8.2 million last month.

There are a few different ways that this level of interest in shorting Aerie Pharmaceuticals shares can be evaluated.

Aerie Pharmaceuticals's "short interest ratio" (SIR)

Aerie Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aerie Pharmaceuticals shares currently shorted divided by the average quantity of Aerie Pharmaceuticals shares traded daily (recently around 691370.63930545). Aerie Pharmaceuticals's SIR currently stands at 12.67. In other words for every 100,000 Aerie Pharmaceuticals shares traded daily on the market, roughly 12670 shares are currently held short.

However Aerie Pharmaceuticals's short interest can also be evaluated against the total number of Aerie Pharmaceuticals shares, or, against the total number of tradable Aerie Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aerie Pharmaceuticals's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Aerie Pharmaceuticals shares in existence, roughly 190 shares are currently held short) or 0.2597% of the tradable shares (for every 100,000 tradable Aerie Pharmaceuticals shares, roughly 260 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Aerie Pharmaceuticals.

Find out more about how you can short Aerie Pharmaceuticals stock.

Aerie Pharmaceuticals share dividends

We're not expecting Aerie Pharmaceuticals to pay a dividend over the next 12 months.

Aerie Pharmaceuticals share price volatility

Over the last 12 months, Aerie Pharmaceuticals's shares have ranged in value from as little as $10.22 up to $26.26. A popular way to gauge a stock's volatility is its "beta".

AERI.US volatility(beta: 0.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerie Pharmaceuticals's is 0.8246. This would suggest that Aerie Pharmaceuticals's shares are less volatile than average (for this exchange).

Aerie Pharmaceuticals overview

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site